Tag: class action

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma’s top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BigBear.ai Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline.

Investors can contact the law firm at no cost to learn more about recovering their losses​

URGN Investors with Losses Encouraged to Contact Hagens Berman

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc (“Reckitt” or the “Company”)(OTC: RBGLY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.